PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2592855-4 1989 TNF suspended with 1% zymosan-activated serum (ZAS) increased PMN migration at low concentrations and decreased migration at high concentrations (control 99 +/- 4.8 microns, n = 9; TNF 0.1 ng/ml 135 +/- 9.4 microns, n = 5, p less than 0.01; TNF 1000 ng/ml 62 +/- 7.5 microns, n = 5, p less than 0.01). Zymosan 22-29 tumor necrosis factor Homo sapiens 0-3 2258638-4 1990 Sixty minutes of preincubation of PMN with 1 microgram/ml TNF alpha or 10 micrograms/ml LPS resulted in similar priming for the respiratory burst elicited by opsonized zymosan, phorbol myristate acetate, zymosan, zymosan-activated serum, aggregated immunoglobulin, and f-met-leu-phe (FMLP) depending on the method of measurement used, i.e., chemiluminescence, production of O2-, and H2O2. Zymosan 168-175 tumor necrosis factor Homo sapiens 58-67 2258638-4 1990 Sixty minutes of preincubation of PMN with 1 microgram/ml TNF alpha or 10 micrograms/ml LPS resulted in similar priming for the respiratory burst elicited by opsonized zymosan, phorbol myristate acetate, zymosan, zymosan-activated serum, aggregated immunoglobulin, and f-met-leu-phe (FMLP) depending on the method of measurement used, i.e., chemiluminescence, production of O2-, and H2O2. Zymosan 204-211 tumor necrosis factor Homo sapiens 58-67 1899427-7 1991 In addition to LPS, rheumatoid factor-containing immune complexes, zymosan, and IL-1 were highly effective in inducing NAP-1/IL-8 production, while IL-3, GM-CSF, tumor necrosis factor (TNF), and IL-2 were somewhat less potent. Zymosan 67-74 tumor necrosis factor Homo sapiens 185-188 2258638-4 1990 Sixty minutes of preincubation of PMN with 1 microgram/ml TNF alpha or 10 micrograms/ml LPS resulted in similar priming for the respiratory burst elicited by opsonized zymosan, phorbol myristate acetate, zymosan, zymosan-activated serum, aggregated immunoglobulin, and f-met-leu-phe (FMLP) depending on the method of measurement used, i.e., chemiluminescence, production of O2-, and H2O2. Zymosan 204-211 tumor necrosis factor Homo sapiens 58-67 2156933-0 1990 Differential augmentation by recombinant human tumor necrosis factor-alpha of neutrophil responses to particulate zymosan and glucan. Zymosan 114-121 tumor necrosis factor Homo sapiens 47-74 30402800-6 2019 TNFalpha production was measured at baseline and after stimulation with the TLR2 agonists: peptidoglycan, lipoteichoic acid, Pam3CysK, Zymosan A and the TLR4 agonist lipopolysaccharide (LPS). Zymosan 135-144 tumor necrosis factor Homo sapiens 0-8 27916353-7 2016 Healthy volunteer cultures had 2-3-fold greater levels of IL-6 and TNFalpha than subject cultures when stimulated with zymosan (TLR2 agonist) or LPS (TLR4 agonist). Zymosan 119-126 tumor necrosis factor Homo sapiens 67-75 23740089-3 2013 Our results showed that when differentiated HL-60 (dHL-60) cells were primed with TNF-alpha for 10 min, ROS production induced by zymosan A or phorbol myristate acetate (PMA) was enhanced in a TNF-alpha-dose-dependent manner. Zymosan 130-139 tumor necrosis factor Homo sapiens 82-91 25092526-8 2014 RESULTS: Mannan, beta-glucans (curdlan), chitosan, and zymosan induced the secretion of interleukin (IL)-1beta, IL-6, IL-23, IL-10, and tumor necrosis factor-alpha by PBMCs. Zymosan 55-62 tumor necrosis factor Homo sapiens 136-163 26183538-2 2015 To study the functional mechanism of beta-glucan in immune stimulation, the effect of zymosan on dendritic cell (DC) was investigated by monitoring the production of TNF-alpha, a pro-inflammatory cytokine. Zymosan 86-93 tumor necrosis factor Homo sapiens 166-175 26183538-5 2015 Especially, Dectin-1, a beta-glucan receptor, was upregulated during DC differentiation, and mediated zymosan-induced TNF-alpha production, which was inhibited by silencing of dectin-1. Zymosan 102-109 tumor necrosis factor Homo sapiens 118-127 26183538-7 2015 Simultaneous treatment of zymosan and PMA enhanced the nuclear translocation of NF-kappaB subunits, p50 and p65, mediating the increase of TNF-alpha production. Zymosan 26-33 tumor necrosis factor Homo sapiens 139-148 26183538-8 2015 Bay 11-7082, an NF-kappaB inhibitor, blocked morphological changes and TNF-alpha production induced by zymosan and/or PMA treatment. Zymosan 103-110 tumor necrosis factor Homo sapiens 71-80 26183538-10 2015 Simultaneous phosphorylation of separate IKK subunits by co-treatment of zymosan and PMA resulted in cooperative activation of NF-kappaB and TNF-alpha production. Zymosan 73-80 tumor necrosis factor Homo sapiens 141-150 23740089-3 2013 Our results showed that when differentiated HL-60 (dHL-60) cells were primed with TNF-alpha for 10 min, ROS production induced by zymosan A or phorbol myristate acetate (PMA) was enhanced in a TNF-alpha-dose-dependent manner. Zymosan 130-139 tumor necrosis factor Homo sapiens 193-202 20224557-8 2010 In addition, monocytes from hypertensive women homozygous for the 249Ser allele showed a lower release of tumor necrosis factor-alpha and interleukin-6 in response to zymosan (TLR6 agonist), but not to lipopolysaccharide (TLR4 agonist). Zymosan 167-174 tumor necrosis factor Homo sapiens 106-133 22629855-3 2012 TNF-alpha production under myelopeptide effect was lowered in cultures with 150 mkg/ml zymosan. Zymosan 87-94 tumor necrosis factor Homo sapiens 0-9 22787557-2 2012 We assert that hydrogen sulfide plays an important role in regulating macrophage function in response to subsequent inflammatory stimuli, promoting clearance of leukocyte infiltrate and reducing TNF-alpha levels in vivo following zymosan-challenge. Zymosan 230-237 tumor necrosis factor Homo sapiens 195-204 21911260-12 2011 A-833834 was also efficacious in suppressing TNF-alpha release in mouse serum following oral administration in zymosan-induced peritonitis. Zymosan 111-118 tumor necrosis factor Homo sapiens 45-54 21525379-5 2011 The purified PLT ectosomes (PLT-Ect) reduced the release of TNF-alpha and IL-10 by macrophages activated with LPS or zymosan A. Zymosan 117-126 tumor necrosis factor Homo sapiens 60-69 17049124-5 2006 RESULTS: The peptide has the ability to interact with the NF-kappaB p50 subunit and can effectively inhibit TNF-alpha and IL-6 production in the THP-1 cell line, PMA-induced ear edema and zymosan A-induced peritonitis in mice. Zymosan 188-197 tumor necrosis factor Homo sapiens 108-117 19854233-11 2010 In contrast to the result in human glioma cells, bradykinin inhibits the zymosan-induced expression of TNF-alpha and IL-1beta in rat astrocytes, which shows a species-dependent manner. Zymosan 73-80 tumor necrosis factor Homo sapiens 103-112 19410299-5 2009 Zymosan enhanced dectin-1/TLR2/TLR4 expression and TNF-alpha/IL-10 production in all of three types of cell, whereas p-beta-glucan increased dectin-1/TLR4 and TNF-alpha/IL-12 production in AMs but inhibited IL-10 in mDCs. Zymosan 0-7 tumor necrosis factor Homo sapiens 51-60 19480711-7 2009 TNF production, however, did not show an age-associated decline, but increased significantly with age in response to co-stimulation with LPS and zymosan. Zymosan 145-152 tumor necrosis factor Homo sapiens 0-3 18515326-10 2008 ; 15 pmol/cavity) also decreased zymosan-induced TNF-alpha production within 6 h, keratinocyte-derived chemokine/CXCL1 production within 24 h, and leukotriene B(4) at both time-points. Zymosan 33-40 tumor necrosis factor Homo sapiens 49-58 19854233-9 2010 Bradykinin increased the zymosan-induced expression of TNF-alpha, and interleukin 1beta (IL-1beta) but did not affect the expression of interleukin 6 (IL-6) or interleukin 10 (IL-10). Zymosan 25-32 tumor necrosis factor Homo sapiens 55-64 18685086-6 2008 In vitro, they were taken up by macrophages, and they significantly inhibited the activation of these macrophages by zymosan A and LPS, as shown by a significant drop in TNF-alpha and IL-8 release (respectively, 80% and 76% inhibitions). Zymosan 117-126 tumor necrosis factor Homo sapiens 170-179 18256754-1 2007 The production of TNF-alpha and IFN-alpha cytokines by peripheral blood mononuclears in response to stimulation by TLR2/6, TLR4, TLR5, TLR9 ligands (zymosan, LPS, flagellin, and CpG-oligodeoxynucleotide, respectively) was studied in donors and patients with common variable immunodeficiency. Zymosan 149-156 tumor necrosis factor Homo sapiens 18-27 16849509-5 2006 The neonatal adenosine system also inhibits TNF-alpha production in response to whole microbial particles known to express TLR2 agonist activity, including Listeria monocytogenes, Escherichia coli (that express BLPs), and zymosan particles. Zymosan 222-229 tumor necrosis factor Homo sapiens 44-53 15683545-7 2005 Cells were stimulated with lipopolysaccharide (LPS) or zymosan, either alone or in combination with Prolastin, native AAT or polymerised AAT for 18 h, and analysed to determine the release of TNFalpha, IL-1beta and IL-8. Zymosan 55-62 tumor necrosis factor Homo sapiens 192-200 16480927-4 2006 Elevated TNFalpha production was found in response to LTA and Zymosan in 48% of active Crohn"s disease and ulcerative colitis patients when compared to inactive patients or controls. Zymosan 62-69 tumor necrosis factor Homo sapiens 9-17 16713974-2 2006 We report that IFN-gamma augments induction of TNFalpha by TLR ligands, immune complexes, and zymosan by suppressing IL-10 production and thereby interrupting Stat3-mediated feedback inhibition. Zymosan 94-101 tumor necrosis factor Homo sapiens 47-55 16501050-8 2006 Zymosan induced the expression of tumor necrosis factor alpha (TNF-alpha), TNF-beta, IL-10, IL-6, and MCP-2/CCL8, whereas the cytokine signature of C3bi-coated zymosan also included interferon-inducible protein 10/CXC chemokine ligand 10, platelet-derived growth factor-BB, and I-309/CCL1. Zymosan 0-7 tumor necrosis factor Homo sapiens 34-61 16501050-8 2006 Zymosan induced the expression of tumor necrosis factor alpha (TNF-alpha), TNF-beta, IL-10, IL-6, and MCP-2/CCL8, whereas the cytokine signature of C3bi-coated zymosan also included interferon-inducible protein 10/CXC chemokine ligand 10, platelet-derived growth factor-BB, and I-309/CCL1. Zymosan 0-7 tumor necrosis factor Homo sapiens 63-72 15102856-4 2004 Using this assay, together with in vitro kinase assays and immunochemical studies, we report that p38 MAPK plays a critical role in TNFalpha priming of the human and porcine NADPH oxidase for superoxide production in response to complement-opsonized zymosan (OpZ), but little, if any, role in neutrophil priming by platelet-activating factor (PAF) for OpZ-dependent responses. Zymosan 250-257 tumor necrosis factor Homo sapiens 132-140 12817025-0 2003 Direct binding of Toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A. Zymosan 55-62 tumor necrosis factor Homo sapiens 97-106 11948463-4 2002 Incubation of IFN-gamma-primed MonoMac-6 cells with serum-opsonized zymosan or EGP-2-directed, mouse IgG2a-opsonized, EGP-2-positive tumor cells resulted in the production of ROS and TNF-alpha and induced E-selectin and ICAM-1 expression on HUVECs. Zymosan 68-75 tumor necrosis factor Homo sapiens 183-192 12428246-8 2002 However, coincubation with MSU led to a significant suppression of zymosan-induced TNFalpha secretion (P = 0.009) from macrophages but not monocytes. Zymosan 67-74 tumor necrosis factor Homo sapiens 83-91 12719478-3 2003 Here we show that Dectin-1 mediates the production of TNF-alpha in response to zymosan and live fungal pathogens, an activity that occurs at the cell surface and requires the cytoplasmic tail and immunoreceptor tyrosine activation motif of Dectin-1 as well as Toll-like receptor (TLR)-2 and Myd88. Zymosan 79-86 tumor necrosis factor Homo sapiens 54-63 12406900-4 2003 In contrast, the TNF-alpha response to zymosan or Staphylococcus aureus as well as the interleukin-6 (IL-6) and IL-8 responses to endotoxin were unaffected by ubiquitin. Zymosan 39-46 tumor necrosis factor Homo sapiens 17-26 11792769-4 2002 At the beginning of the study (day 0), both constitutive and serum-treated zymosan (STZ) stimulated tumor necrosis factor alpha (TNF-alpha) synthesis were assessed in PMO isolated from 12-h dwell effluent (with 1.36% glucose) in all patients. Zymosan 75-82 tumor necrosis factor Homo sapiens 100-127 9891002-8 1999 The physiologic relevance of these findings was demonstrated by a similar increase in DIF-associated PLD activity after stimulation of intact U937 cells with opsonized zymosan. Zymosan 168-175 tumor necrosis factor Homo sapiens 86-89 11792769-4 2002 At the beginning of the study (day 0), both constitutive and serum-treated zymosan (STZ) stimulated tumor necrosis factor alpha (TNF-alpha) synthesis were assessed in PMO isolated from 12-h dwell effluent (with 1.36% glucose) in all patients. Zymosan 75-82 tumor necrosis factor Homo sapiens 129-138 11699074-5 2001 The effect was both stimulus and species dependent, as TNF alpha secretion was attenuated by PDTC in human THP-1 cells and in murine cells stimulated with zymosan. Zymosan 155-162 tumor necrosis factor Homo sapiens 55-64 11207306-3 2001 More interestingly, when neutrophils were pretreated with TNF-alpha for 1-2 min at 37 degrees C and then were exposed to a variety of agents such as immobilized IgG, IgG-coated erythrocytes, complement-treated erythrocytes, zymosan, PMA, zymosan-activated serum, fMLP, Escherichia coli, and GM-CSF for 3 h at 37 degrees C, a marked stimulation of apoptosis was observed. Zymosan 224-231 tumor necrosis factor Homo sapiens 58-67 11207306-3 2001 More interestingly, when neutrophils were pretreated with TNF-alpha for 1-2 min at 37 degrees C and then were exposed to a variety of agents such as immobilized IgG, IgG-coated erythrocytes, complement-treated erythrocytes, zymosan, PMA, zymosan-activated serum, fMLP, Escherichia coli, and GM-CSF for 3 h at 37 degrees C, a marked stimulation of apoptosis was observed. Zymosan 238-245 tumor necrosis factor Homo sapiens 58-67 10675677-6 2000 TNFalpha production increased on exposure to zymosan, LPS and LPS-phorbol myristate acetate, though not on exposure to LB. Zymosan 45-52 tumor necrosis factor Homo sapiens 0-8 11493622-6 2001 LPS, zymosan, and PMA caused marked and dose-dependent increases in TNF-alpha and IL-10 production. Zymosan 5-12 tumor necrosis factor Homo sapiens 68-77 11493622-7 2001 Addition of OX-RBC augmented the LPS-, zymosan-, and PMA-induced TNF-alpha release by approximately 100%. Zymosan 39-46 tumor necrosis factor Homo sapiens 65-74 10824456-5 2000 The amounts of drained TNF-alpha and IL-6 in the lymph peaked at 2-4 hr and 4-8 hr after zymosan administration, respectively. Zymosan 89-96 tumor necrosis factor Homo sapiens 23-32 10824456-7 2000 The amounts of drained TNF-alpha and IL-10 in the mesenteric lymph were significantly correlated with the dosage of zymosan. Zymosan 116-123 tumor necrosis factor Homo sapiens 23-32 10620552-4 2000 Median stimulated TNFalpha values (serum-treated zymosan [STZ], 10 microgram/mL) were 1,894.6, 567.3, and 554.5 pg TNFalpha/10(6) PMO in the same groups, respectively. Zymosan 49-56 tumor necrosis factor Homo sapiens 115-123 9744647-4 1998 The combination of Fragmin and zymosan also induced significantly greater concentrations of IL-1beta (97+/-24) and TNFalpha (2.9+/-.8), but not IL-8 (2.0+/-15). Zymosan 31-38 tumor necrosis factor Homo sapiens 115-123 9613706-1 1998 Unstimulated as well as zymosan and LPS-stimulated production of tumor necrosis factor alpha (TNF-alpha) by polymorphonuclear cells (PMNs) was investigated in breast cancer patients. Zymosan 24-31 tumor necrosis factor Homo sapiens 65-92 9613706-4 1998 Zymosan and LPS-stimulated PMNs of cancer patients were found to produce significantly lower amounts of TNF-alpha, as compared with PMNs of healthy control. Zymosan 0-7 tumor necrosis factor Homo sapiens 104-113 9613706-1 1998 Unstimulated as well as zymosan and LPS-stimulated production of tumor necrosis factor alpha (TNF-alpha) by polymorphonuclear cells (PMNs) was investigated in breast cancer patients. Zymosan 24-31 tumor necrosis factor Homo sapiens 94-103 8688912-2 1995 Zymosan, phorbol ester and fluoride induced the formation and accumulation of oxygen radicals intra- and extracellularly, ionomycin and lipopolysaccharide led to an intracellular accumulation of oxygen radicals, while after arachidonic acid and tumor necrosis factor-alpha, no reactive oxygen species were formed. Zymosan 0-7 tumor necrosis factor Homo sapiens 245-272 9552003-7 1998 In contrast, while IL-8 production in response to S. cerevisiae and zymosan was enhanced in the presence of TNF-alpha, no MIP-1alpha was produced. Zymosan 68-75 tumor necrosis factor Homo sapiens 108-117 8925407-6 1996 Pre-treatment with either DiC8 or TNF alpha dose-dependently augmented the zymosan-stimulated release of LTB4 from PMN. Zymosan 75-82 tumor necrosis factor Homo sapiens 34-43 7692988-3 1993 LPS-tolerant monocytes were still capable of producing TNF when restimulated with zymosan. Zymosan 82-89 tumor necrosis factor Homo sapiens 55-58 7562546-4 1995 We show that, in marked contrast with ibuprofen, flurbiprofen and indomethacin which all significantly enhanced TNF production, the two benzamide derivatives tested, JM34 and JM42, significantly inhibited TNF-alpha production by zymosan or lipopolysaccharide-activated M phi. Zymosan 229-236 tumor necrosis factor Homo sapiens 205-214 7829905-9 1994 The CL responses stimulated with non-opsonized zymosan or P. aeruginosa were enhanced by pretreatment with TNF-alpha and LPS in healthy young adults. Zymosan 47-54 tumor necrosis factor Homo sapiens 107-116 7927986-3 1994 In addition, NLD and zymosan induced TNF alpha secretion which was impaired by a PTK inhibitor, tyrphostin. Zymosan 21-28 tumor necrosis factor Homo sapiens 37-46 8025949-10 1994 PB-PMNs in culture also showed mRNA expression for IL-1 alpha, IL-1 beta, and TNF alpha in a time- and dose-dependent manner, especially after stimulation with zymosan. Zymosan 160-167 tumor necrosis factor Homo sapiens 78-87 8490103-5 1993 The results indicate that inhibition of PKC diminished LPS- or zymosan- induced TNF alpha production in a concentration-dependent manner. Zymosan 63-70 tumor necrosis factor Homo sapiens 80-89 8335923-2 1993 For example, after exposure to the inflammatory particulate stimulus zymosan (or its derivative beta 1,3-glucan), monocyte/macrophages synthesize and release lysosomal hydrolases, mobilize arachadonic acid, and secrete cytokines such as TNF-alpha and IL-8. Zymosan 69-76 tumor necrosis factor Homo sapiens 237-246 8387795-1 1993 Addition of BAPTA/AM to liver macrophages lowered the level of [Ca2+]i and induced a translocation and inactivation of protein kinase C. The phorbol ester- and zymosan-induced release of arachidonic acid, prostaglandin E2 and superoxide, the formation of inositol phosphates upon addition of zymosan and the lipopolysaccharide-induced synthesis of TNF-alpha was inhibited by pretreatment of the cells with BAPTA/AM. Zymosan 160-167 tumor necrosis factor Homo sapiens 348-357 8490103-3 1993 In the present study, the role of protein kinase C (PKC) in the production of TNF alpha was investigated in human peripheral blood monocytes stimulated with either LPS or zymosan. Zymosan 171-178 tumor necrosis factor Homo sapiens 78-87 8490103-9 1993 These data strongly suggest that an initial step in TNF alpha production by human monocytes challenged with physiological stimulants, such as LPS and zymosan, involves a PKC-dependent mechanism. Zymosan 150-157 tumor necrosis factor Homo sapiens 52-61 1334475-2 1992 Preincubation of PMNs with n-TNF for 3 min increased PMN-derived superoxide generation induced by phorbol myristate acetate, A23187, opsonized zymosan and N-formyl-methionyl-leucyl-phenylalanine in a concentration dependent manner (0.5-50 Japan reference units/ml of n-TNF). Zymosan 143-150 tumor necrosis factor Homo sapiens 29-32 1320039-3 1992 In contrast to PMA, zymosan induces the generation of superoxide in unprimed BMM, as well as in TNF alpha-primed BMM and RPM. Zymosan 20-27 tumor necrosis factor Homo sapiens 96-105 1312809-2 1992 When HPPMN were exposed to recombinant human tumor necrosis factor alpha (rHuTNF-alpha) or recombinant human granulocyte colony stimulating factor (rG-CSF), they underwent priming and the rate of superoxide anion (O.-2) generation was increased by subsequent exposure to formyl-methionyl-leucyl-phenylalanine (FMLP) or opsonized zymosan (OZ). Zymosan 329-336 tumor necrosis factor Homo sapiens 45-72 1347552-2 1992 In this study, we showed that human monocytes produced TNF-alpha in response to zymosan, a particulate agonist. Zymosan 80-87 tumor necrosis factor Homo sapiens 55-64 1347552-3 1992 Protein kinase C (PKC) seems to play a regulatory role in zymosan-induced TNF-alpha secretion. Zymosan 58-65 tumor necrosis factor Homo sapiens 74-83 1347552-4 1992 The pretreatment of monocytes with PMA induced a dose-dependent inhibition of zymosan-stimulated TNF production. Zymosan 78-85 tumor necrosis factor Homo sapiens 97-100